Hyperprolactinaemia in Antipsychotic-Treated Patients: Guidelines for Avoidance and Management

ISSN： 1172-7047

Source： CNS Drugs, Vol.10, Iss.3, 1998-09, pp. : 209-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Atropinic (anticholinergic) burden in antipsychotic‐treated patients

Fundamental & Clinical Pharmacology, Vol. 32, Iss. 1, 2018-02 ,pp. : 114-119

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management

By Peter M. Haddad Angelika Wieck

Drugs, Vol. 64, Iss. 20, 2004-01 ,pp. : 2291-2314

Adis International

Access to resources Recommend Favorite

Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: a prospective population-based cohort study from Italy

By Rafaniello Concetta Lombardo Flavia Ferrajolo Carmen Sportiello Liberata Parretta Elisabetta Formica Ranieri Potenza Simona Rinaldi Barbara Irpino Antonio Raschetti Roberto Vanacore Nicola Rossi Francesco Capuano Annalisa

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 187-195

Springer Publishing Company

Access to resources Recommend Favorite

Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents

By Gianfrancesco F.

PharmacoEconomics, Vol. 20, Iss. 6, 2002-06 ,pp. : 413-427

Adis International

Access to resources Recommend Favorite

Risk of Antipsychotic Drug Use in Patients with Alzheimers Disease Treated with Rivastigmine

By Suh D-C.

Drugs & Aging, Vol. 21, Iss. 6, 2004-01 ,pp. : 395-403

Adis International

Access to resources Recommend Favorite